ABCC2 and ovarian carcinoma: In contrast, ABCC2 rs12762549 is associated with decreased risk of grade 3-4 anemia in additive model (OR = 0.51; 95% CI: 0.33–0.81; p = 0.004) among 290 ovarian cancer patients upon treatment with paclitaxel and carboplatin (Lambrechts et al., 2015).